Show simple item record

dc.contributor.authorRemaley, A.
dc.contributor.authorNorata, Giuseppe
dc.contributor.authorCatapano, A.
dc.date.accessioned2017-08-24T02:20:54Z
dc.date.available2017-08-24T02:20:54Z
dc.date.created2017-08-23T07:21:47Z
dc.date.issued2014
dc.identifier.citationRemaley, A. and Norata, G. and Catapano, A. 2014. Novel concepts in HDL pharmacology. Cardiovascular Research. 103 (3): pp. 423-428.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/55846
dc.identifier.doi10.1093/cvr/cvu141
dc.description.abstract

High-density lipoproteins (HDL) are a target for drug development because of their proposed anti-atherogenic properties. In this review, we will briefly discuss the currently established drugs for increasing HDL-C, namely niacin and fibrates, and some of their limitations. Next, we will focus on novel alternative therapies that are currently being developed for raising HDL-C, such as CETP inhibitors. Finally, we will conclude with a review of novel drugs that are being developed for modulating the function of HDL based on HDL mimetics. Gaps in our knowledge and the challenges that will have to be overcome for these new HDL based therapies will also be discussed. © Published by Oxford University Press on behalf of the European Society of Cardiology 2014.

dc.titleNovel concepts in HDL pharmacology
dc.typeJournal Article
dcterms.source.volume103
dcterms.source.number3
dcterms.source.startPage423
dcterms.source.endPage428
dcterms.source.issn0008-6363
dcterms.source.titleCardiovascular Research
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusOpen access via publisher


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record